Price (delayed)
$2.66
Market cap
$22.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$2.65M
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely
There are no recent dividends present for LSTA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.